Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [11]
- Comments [0]
- Validations
- Western blot [2]
- ELISA [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 500-P135-1MG - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- TRAIL (soluble) Polyclonal Antibody, PeproTech®
- Antibody type
- Polyclonal
- Antigen
- Recombinant full-length protein
- Description
- AA Sequence of recombinant protein: MRERGPQRVA AHITGTRGRS NTLSSPNSKN EKALGRKINS WESSRSGHSF LSNLHLRNGE LVIHEKGFYY IYSQTYFRFQ EEIKENTKND KQMVQYIYKY TSYPDPILLM KSARNSCWSK DAEYGLYSIY QGGIFELKEN DRIFVSVTNE HLIDMDHEAS FFGAFLVG.
- Concentration
- 0.1-1.0 mg/mL
Submitted references Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer.
Membrane-proximal TRAIL species are incapable of inducing short circuit apoptosis signaling: Implications for drug development and basic cytokine biology.
Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells.
Possible novel therapy for malignant gliomas with secretable trimeric TRAIL.
Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL.
Cancer gene therapy using a novel secretable trimeric TRAIL.
Antitumor activity of human CD34+ cells expressing membrane-bound tumor necrosis factor-related apoptosis-inducing ligand.
Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L.
Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guérin-induced antitumor activity.
Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes.
TRAIL: a mechanism of tumor surveillance in an immune privileged site.
Spano C, Grisendi G, Golinelli G, Rossignoli F, Prapa M, Bestagno M, Candini O, Petrachi T, Recchia A, Miselli F, Rovesti G, Orsi G, Maiorana A, Manni P, Veronesi E, Piccinno MS, Murgia A, Pinelli M, Horwitz EM, Cascinu S, Conte P, Dominici M
Scientific reports 2019 Feb 11;9(1):1788
Scientific reports 2019 Feb 11;9(1):1788
Membrane-proximal TRAIL species are incapable of inducing short circuit apoptosis signaling: Implications for drug development and basic cytokine biology.
Tatzel K, Kuroki L, Dmitriev I, Kashentseva E, Curiel DT, Goedegebuure SP, Powell MA, Mutch DG, Hawkins WG, Spitzer D
Scientific reports 2016 Mar 3;6:22661
Scientific reports 2016 Mar 3;6:22661
Targeting of XIAP combined with systemic mesenchymal stem cell-mediated delivery of sTRAIL ligand inhibits metastatic growth of pancreatic carcinoma cells.
Mohr A, Albarenque SM, Deedigan L, Yu R, Reidy M, Fulda S, Zwacka RM
Stem cells (Dayton, Ohio) 2010 Nov;28(11):2109-20
Stem cells (Dayton, Ohio) 2010 Nov;28(11):2109-20
Possible novel therapy for malignant gliomas with secretable trimeric TRAIL.
Jeong M, Kwon YS, Park SH, Kim CY, Jeun SS, Song KW, Ko Y, Robbins PD, Billiar TR, Kim BM, Seol DW
PloS one 2009;4(2):e4545
PloS one 2009;4(2):e4545
Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL.
Shashkova EV, Kuppuswamy MN, Wold WS, Doronin K
Cancer gene therapy 2008 Feb;15(2):61-72
Cancer gene therapy 2008 Feb;15(2):61-72
Cancer gene therapy using a novel secretable trimeric TRAIL.
Kim CY, Jeong M, Mushiake H, Kim BM, Kim WB, Ko JP, Kim MH, Kim M, Kim TH, Robbins PD, Billiar TR, Seol DW
Gene therapy 2006 Feb;13(4):330-8
Gene therapy 2006 Feb;13(4):330-8
Antitumor activity of human CD34+ cells expressing membrane-bound tumor necrosis factor-related apoptosis-inducing ligand.
Carlo-Stella C, Lavazza C, Di Nicola M, Cleris L, Longoni P, Milanesi M, Magni M, Morelli D, Gloghini A, Carbone A, Gianni AM
Human gene therapy 2006 Dec;17(12):1225-40
Human gene therapy 2006 Dec;17(12):1225-40
Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L.
Kemp TJ, Ludwig AT, Earel JK, Moore JM, Vanoosten RL, Moses B, Leidal K, Nauseef WM, Griffith TS
Blood 2005 Nov 15;106(10):3474-82
Blood 2005 Nov 15;106(10):3474-82
Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guérin-induced antitumor activity.
Ludwig AT, Moore JM, Luo Y, Chen X, Saltsgaver NA, O'Donnell MA, Griffith TS
Cancer research 2004 May 15;64(10):3386-90
Cancer research 2004 May 15;64(10):3386-90
Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes.
Armeanu S, Lauer UM, Smirnow I, Schenk M, Weiss TS, Gregor M, Bitzer M
Cancer research 2003 May 15;63(10):2369-72
Cancer research 2003 May 15;63(10):2369-72
TRAIL: a mechanism of tumor surveillance in an immune privileged site.
Lee HO, Herndon JM, Barreiro R, Griffith TS, Ferguson TA
Journal of immunology (Baltimore, Md. : 1950) 2002 Nov 1;169(9):4739-44
Journal of immunology (Baltimore, Md. : 1950) 2002 Nov 1;169(9):4739-44
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot: To detect Human sTRAIL/Apo2L by Western Blot analysis TRAIL (soluble) Polyclonal Antibody (Product # 500-P135-1MG) can be used at a concentration of 0.1-0.2 µg/mL. Used in conjunction with compatible secondary reagents the detection limit for Recombinant Human sTRAIL/Apo2L is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot: To detect Human sTRAIL/Apo2L by Western Blot analysis TRAIL (soluble) Polyclonal Antibody (Product # 500-P135-1MG) can be used at a concentration of 0.1-0.2 µg/mL. Used in conjunction with compatible secondary reagents the detection limit for Recombinant Human sTRAIL/Apo2L is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Sandwich ELISA: To detect Human sTRAIL/Apo2L by sandwich ELISA (using 100 µL/well antibody solution) a concentration of 0.5-2.0 µg/mL of TRAIL (soluble) Polyclonal Antibody (Product # 500-P135-1MG) is required. This antigen affinity purified antibody, in conjunction with PeproTech TRAIL (soluble) Polyclonal Antibody, Biotin (Product # 500-P135BT-1MG) as a detection antibody, allows the detection of at least 0.2-0.4 ng/well of Recombinant Human sTRAIL/Apo2L.
